About half of Americans approve of using weight-loss drugs to treat obesity, AP-NORC poll finds

More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and other brands if they are struggling with obesity or have a health condition tied to weight, but they are not broadly supportive of teens who have obesity using the medications, according to a new poll from The Associated Press-NORC Center for Public Affairs Research.

First-ever ethics checklist developed for portable MRI brain researchers

Portable MRI (pMRI) technologies are rapidly transforming the landscape of neuroscience research, allowing neuroscientists to acquire brain data in community settings outside the hospital for the first time. But as neuroscientists increase access to MRI technology and move their research from a lab environment to broad community settings, they face novel ethical, legal, and societal issues (ELSI).

How GLP-1 medications are transforming diabetes and weight loss treatment

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic, Wegovy, Mounjaro and Zepbound. As obesity rates rise, eligibility expands and curiosity about these medications grows, more people are exploring their potential benefits.